REGN34.SA Regeneron Pharmaceuticals, Inc.
- Market cap
- BRL 532B
- P/E
- 21.0x
- P/B
- 3.03x
- ROE
- 15.8%
- Dividend yield
- 0.25%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is REGN34.SA undervalued?
Graham numberREGN34.SA trades 68.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Regeneron Pharmaceuticals, Inc. fundamental analysis
No fundamental analysis for Regeneron Pharmaceuticals, Inc. yet.
Regeneron Pharmaceuticals, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic r…
Full company profileRegeneron Pharmaceuticals, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Regeneron Pharmaceuticals, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 12.2B | 13.1B | 14.2B | 14.3B | 17.3B |
| Gross Profit | 10.9B | 11.4B | 12.4B | 12.4B | 14.9B |
| Operating Income | 4.74B | 4.05B | 3.99B | 3.58B | 5.65B |
| EBITDA | 5.26B | 4.69B | 5.32B | 5.82B | 6.73B |
| Net Income | 4.34B | 3.95B | 4.41B | 4.50B | 5.30B |
| EPS | 40 | 36 | 40 | 43 | 51 |
| Balance Sheet | |||||
| Total Assets | 29.2B | 33.1B | 37.8B | 40.6B | 44.4B |
| Total Liabilities | 6.55B | 7.11B | 8.41B | 9.30B | 10.9B |
| Shareholders' Equity | 22.7B | 26.0B | 29.4B | 31.3B | 33.5B |
| Cash & Short-term Investments | 7.74B | 10.8B | 9.01B | 8.61B | 3.66B |
| Cash Flow | |||||
| Operating Cash Flow | 5.01B | 4.59B | 4.42B | 4.98B | 4.90B |
| Capital Expenditure | 1.62B | 926M | 882M | 1.21B | 1.24B |
| Free Cash Flow | 3.40B | 3.67B | 3.54B | 3.77B | 3.66B |
| Ratios | |||||
| ROE | 19.1% | 15.2% | 15.0% | 14.4% | 15.8% |
| ROA | 14.9% | 12.0% | 11.7% | 11.1% | 11.9% |
| Net Profit Margin | 35.6% | 30.1% | 31.1% | 31.4% | 30.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Regeneron Pharmaceuticals, Inc. dividends
- Dividend yield
- 0.25%
- Forward dividend
- 0.23 BRL
- Payout ratio
- 8.2%
- Ex-dividend date
- Aug 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 370M | 3.50 | 8.2% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 12:1 on Nov 28, 2022.
Who owns Regeneron Pharmaceuticals, Inc.
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 6.10B
- Free float 5.67B
Regeneron Pharmaceuticals, Inc. company profile
- Company name
- Regeneron Pharmaceuticals, Inc.
- Ticker
- REGN34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15,410
- Fiscal year end
- December
- Address
- 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
- Phone
- 914 847 7000
- Website
- regeneron.com
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Regeneron Pharmaceuticals, Inc. management
10- Dr. Leonard S. Schleifer M.D., Ph.D.Co-Founder, President, CEO & Co-Chairman · born 1953
- Dr. George D. Yancopoulos M.D., Ph.D.Co-Founder, President, Chief Scientific Officer & Co-Chairman · born 1960
- Mr. Christopher R. Fenimore CPAExecutive VP of Finance & CFO · born 1971
- Mr. Joseph J. LaRosa J.D.Executive VP, General Counsel & Secretary · born 1959
- Dr. Andrew J. Murphy Ph.D.Executive VP of Research & Co-Chief Scientific Officer · born 1958
- Mr. Daniel P. Van PlewExecutive VP and GM of Industrial Operations & Product Supply · born 1973
- Mr. Rajesh AhujaSenior Vice President of Quality Assurance & Operations
- Mr. Ryan SteinbergerExecutive VP, Chief Digital & Technology Officer
- Mr. Ryan CroweSenior Vice President of Investor Relations & Strategic Analysis
- Ms. Melissa LoznerSenior VP & Chief Compliance Officer